Alchemia Limited
Description Alchemia Limited, a biotechnology company, engages in the discovery and development of human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies primarily in Australia. The companys technologies include HyACT drug delivery technology that enhances the delivery of chemotherapeutic agents to cancer cells; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. It provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism, and the prophylaxis of DVT in orthopaedic and abdominal surgery. The company also develops HyACT-targeted irinotecan that has completed Phase II clinical trails for the treatment of colorectal cancer. It has collaboration with Monash Institute of Pharmaceutical Science to discover drug candidates for G-Protein coupled receptors; and University of Queensland to discover novel opioid analgesics with reduced side effects. The company was founded in 1995 and is headquartered in Brisbane, Australia. To view the detailed information, you need to SUBSCRIBE with us. |
 |